|International Journal of Cardiology and Lipidology Research (Volume 3 Issue 1)|
|Focus on Pitavastatin|
Angelo Michele Carella, Teresa Marinelli, Armando Melfitano, Michele Di Pumpo, Matteo Conte, Giovanni Modola, Maria Chiara Puntonio and Angelo BenvenutoDOI: http://dx.doi.org/10.15379/2410-2822.2016.03.01.03
Published: 11March 2016
Currently, different statins are available for the treatment of dyslipidemia: Atorvastatin, Simvastatin, Rosuvastatin, Lovastatin, Pravastatin, and Fluvastatin; the newest entry in this class of drugs is Pitavastatin.
The purpose of the present study was to examine the latest evidences on Pitavastatin, more than 10 years after its first marketing and focuses on themost recent evidence regarding its differences with otheravailable statins. A literature review of the last 3 years (January 2013 - January 2016) has been carried out via Pub Med. 193 obtained items were analysed.
Pitavastatin has been studied against other drugs in its class and has demonstrated high potency in reducing LDL-Cholesterol levels and increasing HDL-Cholesterol. Pitavastatin has demonstrated a significant reduction in atherosclerotic plaque volumes and several pleiotropic effects, which suggest its potential benefits in reducing cardiovascular risk.At present, Pitavastatin don’t seem to have adverse effects on glucose metabolism; it has no adverse effects on renal function and currently there is no clinical evidence of Pitavastatin-induced hepatotoxicity. Pitavastatinhas favorable pharmacokinetic and safety profiles and its characteristic structure provides significant efficacy at low doses.
|Pitavastatin, HMG-CoA reductase inhibitors, Statin therapy, Hyperlipidemia, Cardiovascular risk.|